Acquisitions and Investments - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands				1 Months Ended		3 Months Ended		11 Months Ended	12 Months Ended
	May 09, 2022	Apr. 29, 2022	Sep. 14, 2021	Jan. 31, 2023	Sep. 30, 2021	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Dec. 31, 2022
Schedule of Equity Method Investments [Line Items]
Total assets of equity method investees						$ 2,169,670		$ 2,169,670	$ 2,167,259
Total liabilities of equity method investees						617,860		617,860	605,611
Market value						1,500		1,500	1,300
Upfront payment received						237,577	$ 329,219
Transfer of intellectual property and other
Schedule of Equity Method Investments [Line Items]
Upfront payment received						64,826	$ 5,962
LeaderMed | LeaderMed Joint Venture | Corporate Joint Venture
Schedule of Equity Method Investments [Line Items]
Joint venture (in shares)					4,703
Ownership interest in joint venture (as a percent)			47.00%		47.00%
LeaderMed | LeaderMed Joint Venture | Corporate Joint Venture | Transfer of intellectual property and other
Schedule of Equity Method Investments [Line Items]
Upfront payment received			$ 1,000		$ 1,000
Equity Method Investment, Nonconsolidated Investee or Group of Investees
Schedule of Equity Method Investments [Line Items]
Total assets of equity method investees						144,000		144,000	167,100
Total liabilities of equity method investees						47,000		$ 47,000	46,500
Net losses of equity method investees						$ 24,900			$ 101,500
Pharmsynthez
Schedule of Equity Method Investments [Line Items]
Equity method investments (as a percent)						9.00%		9.00%
Cocrystal
Schedule of Equity Method Investments [Line Items]
Equity method investments (as a percent)						3.00%		3.00%
Number of shares into which warrants may be converted (in shares)						33,000		33,000
Non-Invasive Monitoring Systems, Inc.
Schedule of Equity Method Investments [Line Items]
Equity method investments (as a percent)						1.00%		1.00%
Neovasc
Schedule of Equity Method Investments [Line Items]
Equity method investments (as a percent)						0.50%		0.50%
BioCardia, Inc.
Schedule of Equity Method Investments [Line Items]
Equity method investments (as a percent)						1.00%		1.00%
Equity security investments (as a percent)						1.00%		1.00%
Number of shares into which warrants may be converted (in shares)						47,000		47,000	47,000
Xenetic Biosciences, Inc.
Schedule of Equity Method Investments [Line Items]
Equity method investments (as a percent)						3.00%		3.00%
LeaderMed
Schedule of Equity Method Investments [Line Items]
Stock ownership (as a percent)						47.00%
GeneDx Holdings
Schedule of Equity Method Investments [Line Items]
Market value						$ 34,400		$ 34,400
Realized gain for fair value changes in investment						$ 8,300
VBI Vaccines Inc
Schedule of Equity Method Investments [Line Items]
Equity security investments (as a percent)						1.00%		1.00%
ChromaDex
Schedule of Equity Method Investments [Line Items]
Equity security investments (as a percent)						0.10%		0.10%
Eloxx Pharmaceuticals
Schedule of Equity Method Investments [Line Items]
Equity security investments (as a percent)						1.50%		1.50%
CAMP4
Schedule of Equity Method Investments [Line Items]
Equity security investments (as a percent)						2.00%		2.00%
HealthSnap
Schedule of Equity Method Investments [Line Items]
Equity security investments (as a percent)						7.00%		7.00%
InCellDx, Inc
Schedule of Equity Method Investments [Line Items]
Equity method investments (as a percent)						29.00%		29.00%
Number of shares into which warrants may be converted (in shares)						700,000		700,000
Zebra
Schedule of Equity Method Investments [Line Items]
Stock ownership (as a percent)						29.00%
Zebra | Variable Interest Entity, Not Primary Beneficiary
Schedule of Equity Method Investments [Line Items]
Equity method investments (as a percent)						29.00%		29.00%	29.00%
Series A Preferred Stock | Zebra | Variable Interest Entity, Not Primary Beneficiary
Schedule of Equity Method Investments [Line Items]
Investment owned (in shares)						1,260,000		1,260,000
Restricted Stock | Zebra | Variable Interest Entity, Not Primary Beneficiary
Schedule of Equity Method Investments [Line Items]
Shares received as a gift (in shares)						900,000
Common Stock
Schedule of Equity Method Investments [Line Items]
Fair value of shares included in consideration from GeneDx Holdings	$ 221,700
Stock price (in dollars per share)	$ 2.44
GeneDx Holdings
Schedule of Equity Method Investments [Line Items]
Payments to acquire equity securities				$ 5,000
Investment owned, shares purchased (in shares)				14,285,714
GeneDx Holdings | GeneDx Holdings
Schedule of Equity Method Investments [Line Items]
Equity method investments (as a percent)						11.80%		11.80%
GeneDx Holdings | Common Class A
Schedule of Equity Method Investments [Line Items]
Investment owned (in shares)		80,000,000				94,300,000		94,300,000
ModeX Therapeutics Inc
Schedule of Equity Method Investments [Line Items]
Total aggregate consideration	$ 300,000
Total purchase price	221,662
Vested equity awards	2,300
Revenue of acquiree								$ 50,000
Net income of acquiree								$ 19,500
Pro forma net income						$ 30,200
ModeX Therapeutics Inc | Common Stock
Schedule of Equity Method Investments [Line Items]
Fair value of shares included in consideration from GeneDx Holdings	$ 219,400
Stock price (in dollars per share)	$ 2.44
Detect Genomix | GeneDx Holdings
Schedule of Equity Method Investments [Line Items]
Payments to acquire business		$ 150,000
Outstanding shares held (as a percent)		5.00%